Assembly Biosciences, Inc. announced several new senior level hires across the organization. The added team members include Richard Colonno, PhD, as Chief Scientific Officer; Thomas Rollins as Chief Development Officer and Head of the Microbiome Program; Elizabeth Haber Lacy as General Counsel and Vice President of Legal Operations; Wayne Herber, PhD, as Vice President, Biological Manufacturing and Quality; Hongmei Huang, PhD, as Vice President, Information Technology and Informatics; Leping Li, PhD, as Vice President, Discovery; Micah Mackison as Vice President, Corporate Development and Strategy; Eric Ruby as Vice President, Regulatory Affairs and Quality Assurance and Simon Haydar, PhD, as Senior Director, Discovery. Richard Colonno joins Assembly from Presidio Pharmaceuticals, where he served as CSO.

Thomas Rollins joins Assembly from anti-infective drug developer Cubist Pharmaceuticals, where he was Senior Vice President and Global Head, Program and Portfolio Management, chairing the team overseeing global product development. Elizabeth HaberLacy was formerly a partner in the Indianapolis office of law firm Barnes & Thornburg, specializing in corporate and entrepreneurial services, venture and corporate financings and corporate transactions. Prior to Assembly, Dr. Herber was Senior Director, Manufacturing Science & Technology at AstraZeneca Biologics.

Hongmei Huang, PhD, was most recently Senior Director and Global Head of Research IT/Informatics at Janssen (Johnson & Johnson), where she oversaw scientific data management and IT services. Dr. Li joins Assembly from antiviral drug developer Presidio Pharmaceuticals, where he was Vice President of Chemistry and inventor of the HCV NS5A inhibitor ravidasvir. Prior to Assembly, Micah Mackison was Senior Director, Corporate Investment Life Sciences for Jabil, where he was responsible for healthcare M&A and venture investments.

Prior to Assembly, Mr. Ruby was Vice President of Regulatory Affairs at Presidio Pharmaceuticals. Dr. Haydar joins Assembly from Eli Lilly & Co., where he was a Senior Research Advisor before serving as Director, then Senior Director of External Innovation R&D Emerging Markets unit.